18 / 33
AURA Study Phase II Extension Component (Osimertinib)
EGFR
Mutations by Last Prior EGFR-TKI Treatment
0%
20%
40%
60%
80%
100%
Afatinib (n=31)
Erlotinib (n=109)
Gefitinib (n=85)
68%
68%
69%
T790M (-)
T790M (+)
Adapted from Yang JC et al. J Clin Oncol. 2017 Feb 21:JCO2016703223. doi: 10.1200/JCO.2016.70.3223. [Epub ahead of print]
Number of Patients with/without T790M*
*by Central cobas EGFR Mutation Test